Stockreport

Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio, Securing $75 Million to Accelerate Genetic Medicines [Yahoo! Finance]

Janus Henderson Group plc Ordinary Shares  (JHG) 
Last janus henderson group plc ordinary shares earnings: 4/30 04:00 am Check Earnings Report
US:NYSE Investor Relations: snl.com/irw/corporateprofile/4147331
PDF nChroma's lead program, CRMA-1001, is a liver-targeted epigenetic editing therapy with potential for both best-in-class potency and ability to drive functional cures fo [Read more]